Table 4.

Factors for belonging to treatment-resistance group identified by univariable and multivariable logistic regression analyses by treatment group

	TOFA (n=156)				BARI (n=138)
	Univariable analysis		Multivariable analysis		Univariable analysis		Multivariable analysis
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Age	1.03 (0.99–1.06)	0.05	1.01 (0.98–1.05)	0.49	1.02 (0.98–1.06)	0.38
Sex (female)	0.87 (0.33–2.24)	0.77			0.92 (0.28–3.04)	0.89
RA duration	1.00 (0.99–1.01)	0.50	1.00 (0.99–1.01)	0.11	1.00 (0.99–1.00)	0.85	1.00 (0.99–1.01)	0.24
MTX dose	0.94 (0.89–0.99)	0.04	0.97 (0.90–1.04)	0.40	1.00 (0.92–1.07)	0.84
Number of previous bDMARDs used	1.60 (1.20–2.07)	<0.001	1.77 (1.26–2.48)	<0.001	1.31 (0.97–1.78)	0.08	1.41 (0.95–2.10)	0.09
HAQ-DI	2.26 (1.36–3.77)	0.001	1.86 (1.02–3.39)	0.04	2.34 (1.19–4.59)	0.01
CRP	1.13 (1.01–1.27)	0.04	1.10 (0.97–1.26)	0.15	1.11 (0.97–1.27)	0.13
MMP-3	1.00 (0.99–1.00)	0.14			1.00 (0.99–1.00)	0.26
Rheumatoid factor titre	1.00 (0.99–1.00)	0.63			1.00 (0.99–1.00)	0.31
Anti-CCP antibody titre	1.00 (0.99–1.00)	0.96	1.00 (0.99–1.01)	0.23	1.01 (1.00–1.02)	0.03	1.00 (0.99–1.01)	0.09

BARI, baricitinib; bDMARDs, biological disease-modifying antirheumatic drugs; CCP, cyclic citrullinated peptide; CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; MMP-3, matrix metalloproteinase 3; MTX, methotrexate; RA, rheumatoid arthritis; TOFA, tofacitinib.